about
The C5a receptor antagonist PMX205 ameliorates experimentally induced colitis associated with increased IL-4 and IL-10Dietary agents and phytochemicals in the prevention and treatment of experimental ulcerative colitisMultifocal Colonic Wall Abscesses during Anti-Tumor Necrosis Factor (TNF)-α Therapy for a Patient with Ulcerative Colitis: A Very Rare Manifestation of Infectious Complications.Parameters of a severe disease course in ulcerative colitisA novel murine model of inflammatory bowel disease and inflammation-associated colon cancer with ulcerative colitis-like features.Experiences of complementary and alternative medicine in patients with inflammatory bowel disease - a qualitative study.IL-22 is mainly produced by IFNγ-secreting cells but is dispensable for host protection against Mycobacterium tuberculosis infection.Current and emerging drugs for the treatment of inflammatory bowel disease.Dysregulation of anti-inflammatory annexin A1 expression in progressive Crohns DiseaseInflammatory bowel disease professionals' attitudes to and experiences of complementary and alternative medicineDevelopment of a pH-responsive particulate drug delivery vehicle for localized biologic therapy in inflammatory bowel diseaseParasitic helminth cystatin inhibits DSS-induced intestinal inflammation via IL-10(+)F4/80(+) macrophage recruitment.Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study.Trichinella spiralis infection suppressed gut inflammation with CD4(+)CD25(+)Foxp3(+) T cell recruitmentPromising effect of Magliasa, a traditional Iranian formula, on experimental colitis on the basis of biochemical and cellular findings.Anti-inflammatory activity of bioaccessible fraction from Eryngium foetidum leaves.Use of complementary and alternative medicine in Swedish patients with inflammatory bowel disease: a controlled study.Effect of glucans from Caripia montagnei mushroom on TNBS-induced colitis.Targeting intestinal inflammation with CD98 siRNA/PEI-loaded nanoparticles.Use of biological molecules in the treatment of inflammatory bowel disease.Medical and surgical therapy of inflammatory bowel disease in the elderly - prospects and complications.Biologic therapies in non-rheumatic diseases: lessons for rheumatologists?Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy.Curcumin and inflammatory bowel disease: potential and limits of innovative treatments.Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?Oral administration of a non-absorbable plant cell-expressed recombinant anti-TNF fusion protein induces immunomodulatory effects and alleviates nonalcoholic steatohepatitis.The immunization status of patients with IBD is alarmingly poor before the introduction of specific guidelines.Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study.The fecal microbiota as a biomarker for disease activity in Crohn's disease.Role of TNF-Alpha, IFN-Gamma, and IL-10 in the Development of Pulmonary Tuberculosis.Protective effects of Fc-fused PD-L1 on two different animal models of colitis.Natalizumab adverse events are rare in patients with multiple sclerosis.Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis.Anti-inflammatory effects of pomegranate (Punica granatum L.) husk ellagitannins in Caco-2 cells, an in vitro model of human intestine.Resveratrol and inflammatory bowel disease.PD-1 deficiency protects experimental colitis via alteration of gut microbiota.Engineered biomimetic nanovesicles show intrinsic anti-inflammatory properties for the treatment of inflammatory bowel diseases.Inflammatory Bowel Disease and Immunonutrition: Novel Therapeutic Approaches Through Modulation of Diet and the Gut Microbiome.Mesenchymal stem cells and conditioned medium avert enteric neuropathy and colon dysfunction in guinea pig TNBS-induced colitis.
P2860
Q24620635-25E2D487-753F-4396-9372-35CDD67D8641Q27021100-95B1594B-FE54-4D89-8DDC-BE2AFB22B190Q32182441-1A8785C7-67C9-42F3-ABA9-1758584D7F76Q34207852-BD415EDE-3AAB-453F-974E-C4BAE0D9E6D6Q34359061-51C76743-E228-4A59-AFCF-AF798A8AF505Q34410515-F069C875-C6DE-4FEC-86D2-95493A3BB208Q34608524-417E03FA-2DB1-4A65-BFE3-13EE3C03FB77Q34883210-B23C0BB8-BF5C-4209-97D2-EA4E6E33972CQ35018662-13B107AD-2141-40FB-9001-91905B15D627Q35064501-975AD656-2302-43D7-8D57-CCB76FD7516FQ35228674-D5627A5C-6F91-43C2-9719-C8939B0C1148Q35535481-17D60D7D-FF35-4B87-9674-700A610BEDB4Q35541718-4C98DA49-19DF-4B87-AD36-BFF31BBF0FFAQ36445377-B0B1CEFA-F1A0-41D6-8D1B-EC28038C1D14Q36731168-B25696A1-7722-4AE7-9109-184D728EAAD0Q37212245-1D0B4424-6402-4642-9AF1-1DCDBE73C89DQ37312768-FA7CFE4C-6A4C-48E4-A500-D6C1CD70166BQ37645197-8B61EEA6-D286-4222-92A2-1E0A36F36FF9Q37690479-AB05C827-0A50-48A6-BEEF-9B1784329564Q37829470-1730FCF2-C905-4668-8B83-38018A6AACD6Q37875963-8CAD68CE-9663-4407-85FB-1BF4BC0E1559Q37909907-0663A385-FAE1-4F52-99E6-99A4817C8549Q38179468-E99DCB21-91BC-4D71-8F74-E542F0647204Q38292885-D0708AB5-5A68-4907-87C8-57F1DA4A087CQ38918638-2278F62B-8AC4-41F3-9C92-E2D3636D8AC3Q39210713-E1C702CE-D1F5-4268-99C1-1B6CCB5BFDD9Q40327479-79E23CD2-7D52-471F-AC51-81C6071735DAQ41410382-8FEF4E5F-461A-428B-B9F1-53BA56B4F39AQ41447259-3FFC94E1-20C1-4665-AF96-C8F367E7FAEBQ41817065-C782F0B5-451C-45DA-988C-19284E2B2DDEQ42214211-57EBFBE1-0FE6-4837-9AC9-842C20BB3B9DQ45340489-EDA2A5CA-3E8C-4204-9A99-397CE4DDB37BQ45773011-4DF0D172-1EF6-413E-8A1D-22F3020CA0FEQ47577758-5CED683C-6424-40E4-AA5A-4C99A6B24D45Q47871727-C004A20D-0EEF-4F5B-9B3E-A1FD488EAFB3Q49323191-2FEB3EEE-2E41-4BDF-8F68-1688E4475A20Q49971986-57ED08C3-E3E9-4EC6-8EA3-8994FFECFD6FQ52564079-FEE3ED82-EBAF-45CA-B223-5C3110CC6F2DQ53419188-67BB1C4D-43B4-4536-97A8-1C98CB8E09C8
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adverse effects of biologics used for treating IBD.
@en
Adverse effects of biologics used for treating IBD.
@nl
type
label
Adverse effects of biologics used for treating IBD.
@en
Adverse effects of biologics used for treating IBD.
@nl
prefLabel
Adverse effects of biologics used for treating IBD.
@en
Adverse effects of biologics used for treating IBD.
@nl
P2093
P1476
Adverse effects of biologics used for treating IBD.
@en
P2093
Andreas Stallmach
Stefan Hagel
Tony Bruns
P304
P356
10.1016/J.BPG.2010.01.002
P577
2010-04-01T00:00:00Z